https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Microneedles: a smart approach and increasing potential for transdermal drug delivery system https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44995 Wed 26 Oct 2022 09:22:09 AEDT ]]> Integrins are double-edged swords in pulmonary infectious diseases https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52738 Wed 25 Oct 2023 08:40:27 AEDT ]]> Functional relevance of SATB1 in immune regulation and tumorigenesis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33086 Wed 15 Dec 2021 16:08:07 AEDT ]]> Gene therapy and type 1 diabetes mellitus https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33590 Wed 15 Dec 2021 16:08:03 AEDT ]]> Emerging landscape in psoriasis management: from topical application to targeting biomolecules https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44524 Wed 09 Nov 2022 10:21:36 AEDT ]]> Microbiome as therapeutics in vesicular delivery https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33587 Thu 22 Nov 2018 13:41:28 AEDT ]]> Molecular modulators of celastrol as the keystones for its diverse pharmacological activities https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38736 Thu 20 Jan 2022 16:12:34 AEDT ]]> Eucalyptus microcorys leaf extract derived HPLC-fraction reduces the viability of MIA PaCa-2 cells by inducing apoptosis and arresting cell cycle https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33409 Eucalyptus microcorys extract against pancreatic cancer cell lines. In this study, bioassay-guided fractionation of the aqueous crude E. microcorys extract using RP-HPLC and subsequent assessment of the resultant fractions (F1-F5) for their antioxidant activity and cytotoxicity against pancreatic cancer cell lines were performed. The molecular mechanisms associated with the cytotoxicity was characterised by studying the effects of the most potent fraction-1 (F1) on apoptosis and cell cycle profiles as well as its phytochemical constituents by LC-ESI/MS/MS. F1 displayed significantly greater antioxidant activity in three different assays (p < 0.05). Moreover, F1 exhibited significantly greater antiproliferative activity (IC₅₀ = 93.11 ± 3.43 µg/mL) against MIA PaCa-2 cells compared to the other four fractions (p < 0.05). F1 induced apoptosis by regulating key apoptotic proteins- Bcl-2, Bak, Bax, cleaved PARP, procaspase-3 and cleaved caspase-3 in MIA PaCa-2 cells, suggesting the involvement of intrinsic mitochondrial apoptotic pathway and arrested cells at G2/M phase. A combination of gemcitabine and F1 exerted a greater effect on apoptosis and cell cycle arrest than F1 or gemcitabine alone (p < 0.05). LC-ESI/MS/MS revealed the tentative identities of phytochemicals present in F1 and their similarities with the phenolic compounds previously reported in Eucalyptus with antipancreatic cancer activity. Our study shows that the polyphenol and antioxidant-rich fraction of E. microcorys extract is a promising candidate for developing mono or combination therapies against pancreatic cancer.]]> Thu 09 Dec 2021 11:03:58 AEDT ]]> MicroRNAs as biological regulators in skin disorders https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33586 Thu 03 Feb 2022 12:21:26 AEDT ]]> Multi-drug resistant Mycobacterium tuberculosis & oxidative stress complexity: emerging need for novel drug delivery approaches https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33588 Mycobacterium tuberculosis, Mtb) treatment involves multiple drug regimens for a prolonged period. However, the therapeutic benefit is often limited by poor patient compliance, subsequently leading to treatment failure and development of antibiotic resistance. Notably, oxidative stress is a crucial underlying factor that adversely influences the various treatment regimens in tuberculosis. Little information is available with advanced drug delivery systems that could be effectively utilized, in particular, for targeting the oxidative stress in tuberculosis. Thus, this presents an opportunity to review the utility of various available, controlled-release drug delivery systems (e.g., microspheres, liposomes, niosomes, solid lipid nanoparticles, dendrimers) that could be beneficial in tuberculosis treatments. This will help the biological and formulation scientists to pave a new path in formulating a treatment regimen for multi-drug resistant Mtb.]]> Thu 03 Feb 2022 12:21:12 AEDT ]]> Pharmacological evaluation of aqueous extract of syzigium cumini for its antihyperglycemic and antidyslipidemic properties in diabetic rats fed a high cholesterol diet—Role of PPARγ and PPARα https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31020 Sat 24 Mar 2018 07:34:51 AEDT ]]> Design, synthesis and biological evaluation of novel pyxinol derivatives with anti-heart failure activity https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38317 via esterification. Among them, compounds 2e (IC50 =105 nM) and 3b (IC50 =114 nM) displayed excellent ACE inhibitory activity in vitro, and exhibited non-toxic to H9c2 cells. The interactions between ACE and compounds were predicted by molecular docking respectively. In verapamil-induced zebrafish HF model, the activity assay showed that these two derivatives could improve cardiovascular physiological indexes including heart beats, venous congestion, heart dilation, cardiac output, ejection fraction and fractional shortening in a dose-dependent manner. A UPLC-QTOF-MS-based serum metabolomics approach was applied to explore the latent mechanism. A total of 25 differentiated metabolites and 8 perturbed metabolic pathways were identified. These results indicated that pyxinol fatty acid ester derivatives 2e and 3b might be considered as potent drug candidates against heart failure and deserved further research and development.]]> Mon 29 Jan 2024 18:52:01 AEDT ]]> Involvement of epithelia-derived exosomes in chronic respiratory diseases https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49786 Fri 02 Jun 2023 17:27:41 AEST ]]>